Nicoya Lifesciences Acquires LSK Technologies

Nicoya Lifesciences Acquires Applied Photophysics

June 10, 2025

Biotechnology

Nicoya Lifesciences acquired UK-based Applied Photophysics, integrating established biophysical instrumentation (CD, stopped-flow, nanoDSF) with Nicoya's SPR platforms to create a more comprehensive biologics characterization offering. The deal immediately doubles Nicoya's revenue, triples its customer base, establishes Applied Photophysics's Leatherhead site as Nicoya's European hub, and was financed by Nicoya's existing investor syndicate led by Graphite Ventures.

Miltenyi Biotec Acquires lino Biotech

March 22, 2023

Biotechnology

Miltenyi Biotec has acquired 100% of lino Biotech from investors including Roche Venture Fund and Hightech-Grunderfonds. The acquisition brings lino's focal molography biosensor platform into Miltenyi's cell and gene therapy and research-tools portfolio to enhance potency assays and quality-control capabilities.

Quanterix Corporation Acquires Akoya Biosciences

July 8, 2025

Medical Devices

Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.

Lucy Scientific Discovery Acquires BlueSky Wellness

September 12, 2023

Consumer Products

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) agreed to acquire BlueSky Wellness Inc. in an all-stock transaction that will add a portfolio of plant-based wellness CPG brands (Keoni, Keoni Sport, Blush Wellness, AMMA Healing) and e-commerce capabilities. BlueSky shareholders will receive 3.5 million Lucy shares plus up-to-five-year EBITDA-based earnouts; Lucy expects the combined transactions with its High Times IP acquisition to add at least $30 million in revenue and $10 million of EBITDA in the first 12 months.

Discovery Life Sciences Acquires ReachBio Research Labs

April 11, 2023

Biotechnology

Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.

Discovery Life Sciences Acquires QualTek Molecular Laboratories

May 5, 2019

Healthcare Services

Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.